NINofisat Ismaila

Nofisat Ismaila

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Nofisat Ismaila has a total of 339 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Treatment of Stage IB to III Nasopharyngeal Carcinoma: CSCO-ASCO Guideline Update

    by Yu-Pei Chen, Nofisat Ismaila, Shao Hui Huang, Wei Jiang, Brigette Ma, Robert Haddad, Quynh-Thu Le, A. Dimitrios Colevas, Kevin Harrington, Sue S. Yom, et al.

    PURPOSE: To update the 2021 CSCO-ASCO guideline on chemotherapy in combination with radiotherapy for the definitive treatment of non-metastatic nasopharyngeal carcinoma (NPC), incorporating new evidence on radiotherapy techniques and target-volume de-escalation, chemotherapy regimens and their sequencing, adjuvant therapy, and immunotherapy for patients with stage IB-III disease. METHODS: A multidisciplinary Expert Panel reviewed evidence published since the prior guideline, including randomized controlled trials, systematic reviews, meta-analyses, and relevant prospective and retrospective studies. Outcomes of interest included overall survival, failure-free or progression-free survival, locoregional and distant disease control, acute and late toxicities, and patient-reported quality of life. Recommendations were developed using the ASCO guideline development process and Expert Panel consensus. RESULTS: The updated evidence supports: IMRT with image guidance and MRI-based target delineation as core components of definitive treatment; selected response-adapted target delineation following induction chemotherapy; elective nodal de-escalation in appropriately selected patients; risk-adapted chemotherapy sequencing according to stage and biologic risk; cisplatin-based concurrent chemoradiotherapy; gemcitabine–cisplatin (GP) or docetaxel–cisplatin–fluorouracil (TPF) as preferred induction regimens; and selected adjuvant chemotherapy options, including metronomic capecitabine for patients with higher residual post-chemoradiotherapy risk. Several randomized trials evaluating PD-1 inhibitors have demonstrated improved disease-control outcomes, but overall survival data remain immature. RECOMMENDATIONS: This guideline update provides recommendations on radiotherapy technique, dose, imaging, and target delineation; sequencing of additional chemotherapy with radiotherapy; concurrent chemotherapy options; induction chemotherapy regimens and timing; adjuvant chemotherapy options; and the role of immunotherapy. At present, the Panel makes no recommendation for or against routine addition of immunotherapy to induction-concurrent chemoradiotherapy; applicability of the trial evidence, benefits and harms, local approval and access, and patient preferences should guide individualized decisions. Additional information is available at www.ascopubs.org/topics/asco-guidelines/head-neck-cancer .

  • Treatment of Recurrent and/or Metastatic Nasopharyngeal Carcinoma: CSCO and ASCO Joint Guideline

    by Wei Jiang, Nofisat Ismaila, Melvin Lk Chua, Robert Haddad, Quynh-Thu Le, A. Dimitrios Colevas, Nabil F Saba, Kevin Harrington, Shao Hui Huang, Anthony Tc Chan, et al.

    PURPOSE: To provide evidence-based recommendations on first- and subsequent-line systemic therapy, maintenance therapy, locoregional consolidation, and salvage local therapy for patients with recurrent and/or metastatic nasopharyngeal carcinoma (NPC). METHODS: A multidisciplinary Expert Panel convened by CSCO and ASCO reviewed evidence from randomized trials, meta-analyses, systematic reviews, prospective and retrospective studies, and clinical experience. The guideline was informed by a systematic literature review and consensus-based interpretation of efficacy, safety, feasibility, and patient-centered outcomes across scenarios. Outcomes included overall and progression-free survival, response and disease control rates, toxicity, and quality of life. RESULTS: Evidence supports platinum-based chemotherapy plus a programmed cell death protein 1 (PD-1) inhibitor as preferred first-line therapy for medically fit patients. Evidence also supports maintenance strategies after disease control, while treatment selection depends on prior treatment, disease extent, patient fitness, resource availability, and preferences. Selected responders may receive locoregional consolidation radiotherapy or oral maintenance chemotherapy. For isolated locoregional recurrence amenable to local therapy, options include salvage surgery and re-irradiation. RECOMMENDATIONS: Chemotherapy plus a PD-1 inhibitor, followed by maintenance PD-1 inhibition for up to 2 years, should be offered first-line to appropriate patients with recurrent and/or metastatic NPC. Chemotherapy alone may be offered when immunotherapy is unsuitable or declined. Selected patients responding to first-line chemotherapy may receive oral maintenance chemotherapy or locoregional consolidation intensity-modulated radiotherapy. Salvage surgery or re-irradiation is recommended for appropriately selected patients with isolated locoregional recurrence. Subsequent-line options include chemotherapy, PD-1 inhibitors, and antibody-drug conjugates. Treatment should be individualized according to disease setting, prior therapy, expected toxicities, availability, local drug approvals, and patient preferences. Early supportive and specialist interdisciplinary palliative care, where available, should accompany active anticancer treatment for advanced, incurable disease. Additional information is available at www.ascopubs.org/topics/asco-guidelines/head-neck-cancer .

  • Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2026.3.4

    by Joshua Reuss, Nofisat Ismaila, Deborah B Doroshow, Jill Feldman, Gary R. MacVicar, Vanita Noronha, Andreas Saltos, Susan C. Scott, Eric K. Singhi, Jennifer Marie Suga, et al.

    This guideline has been updated. This ASCO Living Guideline is reviewed on an eight-week cycle. Please see the online dynamic version for the latest updates. Living guidelines are developed for selected topic areas with rapidly evolving evidence that drives frequent change in recommended clinical practice. Living guidelines are updated on a regular schedule by a standing expert panel that systematically reviews the health literature on a continuous basis, as described in the ASCO Guidelines Methodology Manual . ASCO Living Guidelines follow the ASCO Conflict of Interest Policy Implementation for Clinical Practice Guidelines . Living Guidelines and updates are not intended to substitute for independent professional judgment of the treating clinician and do not account for individual variation among patients. See appendix for disclaimers and other important information (Appendix I and Appendix II). Updates are published regularly and can be found on the ASCO Publications website .

  • Therapy for Stage IV Non–Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2026.3.3

    by Paul Wheatley-Price, Nofisat Ismaila, Antonio Calles Blanco, Jeremy Cetnar, Terri Conneran, Parth A. Desai, Greg Durm, Hidehito Horinouchi, Humera Khurshid, Swati Kulkarni, et al.

    This guideline has been updated. This ASCO Living Guideline is reviewed on an eight-week cycle. Please see the online dynamic version for the latest updates. Living guidelines are developed for selected topic areas with rapidly evolving evidence that drives frequent change in recommended clinical practice. Living guidelines are updated on a regular schedule by a standing expert panel that systematically reviews the health literature on a continuous basis, as described in the ASCO Guidelines Methodology Manual . ASCO Living Guidelines follow the ASCO Conflict of Interest Policy Implementation for Clinical Practice Guidelines . Living Guidelines and updates are not intended to substitute for independent professional judgment of the treating clinician and do not account for individual variation among patients. See appendix for disclaimers and other important information ( Appendix 1 and Appendix 2 , online only). Updates are published regularly and can be found on the ASCO Publications website .


  • Open Access

    Integrating Artificial Intelligence and Automation Into Living Guideline Development: A Scoping Review of Existing Frameworks, Methods, and Applications

    by Nofisat Ismaila, Syed Arsalan Ahmed Naqvi, Lawrence Mbuagbaw, Jinhui Ma, Lehana Thabane

    Background: Artificial intelligence (AI) and automation offer opportunities to enhance the efficiency, timeliness, and sustainability of living guidelines (LGs). However, how AI and automation have been integrated into existing LG development frameworks remains unclear. This scoping review represents the first step in a broader programme of work aimed at developing a framework which aims to guide responsible and coordinated AI adoption across all phases of LG development. Objective: To identify existing frameworks, methods, and approaches that integrate AI or automation into any stage of LG development. Methods: We conducted a structured search of PubMed, Embase, Web of Science, Scopus, Cochrane Database for Systematic Review and Cochrane Central Register of Controlled Trials from inception to March 12, 2026. We included peer‐reviewed articles describing frameworks, models, or methods that applied AI or automation in the development of LGs. We extracted data into a standardised form, capturing study characteristics, AI methods, targeted guideline processes, and key findings and synthesised findings using a thematic narrative approach. Results: Of 1090 records identified, three studies met the inclusion criteria. The included studies described AI or automation applied to select components of the LG process, to support continuous evidence surveillance, to semi‐automate study screening, and incremental updating of living systematic reviews. None addressed multiple stages of LG development in an integrated manner. Conclusions: Current evidence demonstrates fragmented and narrowly focused AI or automation applications within LG development processes. Our findings highlight opportunities for future work to develop and evaluate more comprehensive frameworks that span multiple stages of the LG lifecycle.

  • Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2026.3.2

    by Sonam Puri, Nofisat Ismaila, Ibrahim Hanna Azar, Janet Freeman-Daily, Naoki Furuya, Sara Kuruvilla, Logan Roof, Ana I. Velazquez, Yubao Wang, Paul Wheatley Price, et al.

    Living guidelines are developed for selected topic areas with rapidly evolving evidence that drives frequent change in recommended clinical practice. Living guidelines are updated on a regular schedule by a standing expert panel that systematically reviews the health literature on a continuous basis, as described in the ASCO Guidelines Methodology Manual . ASCO Living Guidelines follow the ASCO Conflict of Interest Policy Implementation for Clinical Practice Guidelines . Living Guidelines and updates are not intended to substitute for independent professional judgment of the treating clinician and do not account for individual variation among patients. See appendix for disclaimers and other important information ( Appendix I and Appendix II ). Updates are published regularly and can be found on the ASCO Publications website .


  • Therapy for Stage IV Non–Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, 2026.3.1

    by Lyudmila Bazhenova, Nofisat Ismaila, Greg Durm, Janet Freeman-Daily, Hidehito Horinouchi, Gary R. MacVicar, Deebya Raj Mishra, Bruna Pellini, Erin L. Schenk, Navneet Singh, et al.

    Living guidelines are developed for selected topic areas with rapidly evolving evidence that drives frequent change in recommended clinical practice. Living guidelines are updated on a regular schedule by a standing expert panel that systematically reviews the health literature on a continuous basis, as described in the ASCO Guidelines Methodology Manual . ASCO Living Guidelines follow the ASCO Conflict of Interest Policy Implementation for Clinical Practice Guidelines . Living Guidelines and updates are not intended to substitute for independent professional judgment of the treating clinician and do not account for individual variation among patients. See appendix for disclaimers and other important information ( Appendix 1 and Appendix 2 , online only). Updates are published regularly and can be found at https://ascopubs.org/nsclc-non-da-living-guideline .


  • Therapy for Stage IV Non–Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, 2026.3.1

    by Joshua E. Reuss, Nofisat Ismaila, Amith Ahluwalia, Toby Campbell, Jill Feldman, Shirish Gadgeel, Michael Mullane, Carolyn J. Presley, Eric K. Singhi, Jennifer Marie Suga, et al.

    Living guidelines are developed for selected topic areas with rapidly evolving evidence that drives frequent change in recommended clinical practice. Living guidelines are updated on a regular schedule by a standing expert panel that systematically reviews the health literature on a continuous basis, as described in the ASCO Guidelines Methodology Manual . ASCO Living Guidelines follow the ASCO Conflict of Interest Policy Implementation for Clinical Practice Guidelines . Living Guidelines and updates are not intended to substitute for independent professional judgment of the treating clinician and do not account for individual variation among patients. See appendix for disclaimers and other important information ( Appendix 1 and Appendix 2 , online only). Updates are published regularly and can be found at https://ascopubs.org/nsclc-da-living-guideline .


  • Top Cited Papers

    Systemic Treatment of Thyroid Cancer: ASCO Guideline

    by Nabil F. Saba, Nofisat Ismaila, Douglas Adkins, Nishant Agrawal, Neil Akhave, Erik S. Blomain, Maria E. Cabanillas, Amy Chen, Thomas J. Galloway, Guilherme Harada, et al.

    ASCO Guidelines provide recommendations with comprehensive review and analyses of the relevant literature for each recommendation, following the guideline development process as outlined in the ASCO Guidelines Methodology Manual . ASCO Guidelines follow the ASCO Conflict of Interest Policy for Clinical Practice Guidelines . Clinical Practice Guidelines and other guidance (“Guidance”) provided by ASCO is not a comprehensive or definitive guide to treatment options. It is intended for voluntary use by clinicians and should be used in conjunction with independent professional judgment. Guidance may not be applicable to all patients, interventions, diseases, or stages of diseases. Guidance is based on review and analysis of relevant literature and is not intended as a statement of the standard of care. ASCO does not endorse third-party drugs, devices, services, or therapies and assumes no responsibility for any harm arising from or related to the use of this information. See complete disclaimer in Appendix 1 and Appendix 2 (online only) for more . PURPOSE: To provide evidence-based recommendations on the use of systemic therapy in different types of thyroid cancers. METHODS: The American Society of Clinical Oncology convened a multidisciplinary Expert Panel to evaluate the evidence and formulate recommendations. The literature search included studies published between January 1, 2000, and November 5, 2025, and comprised systematic reviews, meta-analyses, randomized controlled trials, and observational studies. Outcomes of interest included overall survival, disease-free survival, and safety. Expert Panel members used available evidence and informal consensus to develop evidence-based guideline recommendations. RESULTS: A total of 66 publications were identified to inform the evidence base for this guideline. RECOMMENDATIONS: Evidence-based recommendations address the use of systemic therapy in patients with well-differentiated, differentiated high-grade or poorly differentiated, anaplastic, and medullary thyroid cancer. Additional information is available at https://ascopubs.org/topics/asco-guidelines/head-neck-cancer .